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Summary.-A study has been made of the thymidine labelling index (TLI) of marrow
blast cells in 201 adults with untreated acute leukaemia. There was no significant
difference between the TLI in 172 patients with acute myeloblastic leukaemia and 29
patients with acute lymphoblastic leukaemia. The TLI did not correlate with the age,
sex, peripheral-blood or marrow blast-cell count, or the platelet count at presenta-
tion. In neither acute myeloblastic leukaemia nor acute lymphoblastic leukaemia
was there any correlation between the TLI and the response to the initial therapy, the
duration of the first complete remission or survival.
THERE IS considerable evidence that in
acute leukaemia there is an accumulation
of non-dividing blast cells which fail to
mature. The earliest cells are proliferating
at a rate comparable to that of normal
cells, but the Gl inter-mitotic phase
becomes prolonged and eventually the
cells cease to divide (Gavosto et al., 1960,
1967; Hillen et al., 1975; Priesler et al.,
1970; Sewell, 1967; Vogler et al., 1974).
Most cytotoxic chemotherapeutic agents
act predominantly on dividing cells.
However, attempts to increase the pro-
portion of dividing cells by drug-induced
synchronization have not improved the
complete-remission rates (Crowther et al.,
1973; Vogler et al., 1976). Neither have
in vitro kinetic measurements been of
predictive value in terms of response to
therapy (Amadori et al., 1978; Crowther
et al., 1975; Vogler et al., 1976). There has,
however, been some dispute as to whether
the thymidine-labelling index (TLI) is of
prognostic value in terms of duration of
remission (Amadori et al., 1978; Cheung
et al., 1972; Crowther et al., 1975; Durie
et al., 1977; Scarife et al., 1980; Vogler
et al., 1976; WVantzin, 1977; Zittoun et al.,
1975).
WVe present here datafrom 201 untreated
adults with acute leukaemia, including
those with acute myeloblastic leukaemia
previously reported. We relate the marrow
TLI to clinical and haematological para-
meters and to the response to therapy.
MATERIALS AND METHODS
Patients
A total of201 adult patients with untreated
acute leukaemia were studied between 1970
and 1976. There were 172 patients with acute
myeloblastic leukaemia (AML) classified ac-
cording to the FAB criteria (Bennett et al.,
1976) (Table II). Of these patients, 91 were
classified as AML (MI and M2), 52 as acute
myelomonocytic leukaemia (M4), 13 as acute
promyelocytic leukaemia (M3), 9 as acute
monoblastic leukaemia (M5) and 7 as erythro-
leukaemia (M6). There were 29 patients with
acute lymphoblastic leukaemia (ALL) of
which 4 were T-cell in type and one Burkitt-
like (Table I).
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TABLE I. Patient data.: ALL (Total 29;
-I "A/r -1 'A -, Thynidine labelling index (TLI)
t9Iv1, 10u
Age (yrs) I
Blasts (%)
Marrow 7
Peripheral blood
WNBC (x 109/1) 0
Platelets ( x 109/1)
TLI
All patients 0
Remitters (n= 22) 0-
Non-remitters (n = 7)
TABLE I.-Patient data:
96M, 761
Age (yrs)
Blasts (0/0)
AMarrow
Peripheral bloocd
WVBC (x 109/1)
Platelets ( x 109/I)
TLI
All patients
Remitters (n=57)
Non-remitters (n= 115)
I') The in vitro TLI ofblast cells in the marrow
Range Median of all 201 patients was assessed before treat-
5-68 21 ment. Marrow was collected into heparinized Medium 199 (Wellcome) containing 125
77-99 jUCi of[3H]dT per ml (sp. act. 5 Ci/mmol) and
0-99 incubated at 37°C for 30 min. Smears were 98-322-8 1756 prepared and after air-drying and methanol
fixation they were coated with K5 emulsion
*5-67 8 (Ilford). Smears were exposed in the dark for
*5-67 7 7 days before developing w-ith D19b de-
4-17 11 veloper (Kodak) and fixing with Hypam
solution (Ilford). Smears were then stained
AML (Total 172; +with Leishman's stain. Background was
') usually less than one grain per cell and
Range AMedian labelled cells rarely had less than 100 grains
16-77 54 per cell. Depending on the proportion of cells
labelled, up to 10,000 cells were counted and
9-99 the TLI expressed as a percentage. Labelled
0-99 cells of the erythroid series and labelled
50398 493.6 lymphocytes were excluded.
1-86 10
1-74 9
1-86 10
Treatmnent
A. Acute myeloblastic leukaernia.-Betw,een
1970 and 1974, patients were treated with
Daunorubicin and cytosine arabinoside (AraC)
for remission induction and consolidation.
This was followed by monthly maintenance
therapy comprising AraC with 6-thioguanine
and AraC with Daunorubicin on alternate
months.
Between 1]974 and 1976, patients wrere
treated w%ith Adriamycin, vincristine, pred-
nisolone and AraC for remission induction
and consolidation, and maintenance chemo-
therapy as above.
From 1970 to 1976 all patients were entered
on to trials of "immunotherapy", some re-
ceiving no immunotherapy, some BCG alone,
and some BCG and allogeneic myeloblasts.
None of these manoeuvres influenced the
duration of the first complete remission.
B. Acute lymphoblastic leukaemia. All
patients were treated with Adriamycin, vin-
cristine, prednisolone and L-asparaginase for
remission induction and consolidation, fol-
lowed by early CNS treatment and continuous
maintenance therapy wAith 6-mercaptopurine,
methotrexate and cyclophosphamide.
The details ofthese treatment programines
have already been published in detail (Crow-
ther et al., 1973; Lister et al., 1978, 1980).
RESULTS
The marrowr TLI in 172 patients with
AML ranged from 1 to 86% (median
10%) and the TLI in 29 adult patients
with ALL ranged from 0-5 to 670% (median
8%). (Fig. 1-5.) There was no significant
difference between the TLI in AML and
ALL.
The TLI did not correlate with age, sex,
the proportion of blasts in the marrow or
70 r
60
* 74/ * 86/
50 F
\J
m
40 1
30 F
20 F
10
0
.Z.
I
vi: .:- Z
REMISSION NO
(57) REMISSION
(115)
FiG. 1. Relationslip betwxeein the pre-treat-
ment TLI of marrow blasts and response to
initial therapy in AML.
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TABLE III.-Breakdown of labelling-index
data: AML
Total
Age (yrs) < 60
>60
Male
Female
% Blasts in marrow
1-80
81-99
% Blasts in
peripheral bloodl
1-70
71-99
Platelets (x 109/1)
<50
>50
Auer rods: present
absent
Pelger: present
absent
Abnormal
chromosomes
90 r
No. of
patients
172
119
53
TLI
A A
Range
1-86
1-86
1-53
Median P
10
9
11
96 1-86 10 0 76 1-56 12
89 1-86 11 0-59
83 1-74
85 1-86 19 }047
76 1-53 1
94 1-56 10 o0-25
77 1-86 10f
39
133
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146
-56
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-86
-54
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FIG. 2. Relationship between the pre-treat-
ment TLI of marrow blasts and the degree
of cytological differentiation in AML.
peripheral blood, or the platelet count in
AML (Table III). There was no correlation
between the TLI and the morphological
subdivisions of AML (Fig. 2).
Fifty-seven patients with AML achieved
complete remission (33%o) but there was
no significant difference between the
median TLI of the remitters (90%) and of
the non-remitters (10%) (Fig. 1). Analysis
ofthe TLI in the 57 patients who achieved
complete remission showed no correlation
between TLI and remission length (Fig.
3). Of the 29 remission patients with a
TLI below 10%, 12 relapsed in less than
8 months, 17 had longer remissions, of
whom 2 are still in remission after 56 and
62 months (Fig. 3). Ofthe 28 patients with
a TLI of 100% or more, 16 relapsed in less
than 8 months, 12 had longer remissions
of whom 3 are still in remission after
49, 64 and 86 months (Fig. 3). (One
patient was killed in a road traffic accident
whilst still in remission.) These differences
were not significant (P=0.4). Of the 57
patients who achieved complete remission,
46 were classified as MI and M2 or M4.
Analysis of this group showed that 15/23
patients with a TLI > 10% relapsed in
under 8 months, whereas 9/23 patients
with a TLI <10% relapsed in under 8
months. There was, however, no correla-
tion between the length of remission and
TLI. Analysis of the survival of the 57
remission patients showed no significant
difference between those with a TLI
< 100% and those with a TLI of 100% or
more (P= 0 7).
The TLI in all 172 patients with AML
showed no correlation with survival. The
survival of patients with a TLI of less
than 100% and those with a TLI of 100% or
more was not significantly different (P=
0 6) (Fig. 4).
The study included 29 adult patients
with ALL, of whom 22 (79%) achieved
complete remission. The TLI did not
correlate with age, sex, the proportion of
blasts in the marrow or peripheral blood,
or the platelet count. There was no sig-
nificant difference between the TLI of
remitters and non-remitters (Fig. 5).
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FIG. 3.-Relationship between the pre-treatment TLI of marrow blasts and length of first remission
in AML (0, still in remission).
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FIG. 4.-Comparison of survival curves in AML patients witi a TLI of less than 1000 vs patients
with a TLI of 1000 or more
Analysis of TLI in the 22 patients who
achieved complete remission showed no
correlation between the TLI and remission
length (Fig. 6). There was no correlation
between the TLI and survival in the 29
patients studied (Fig. 7).
DISCUSSION
Our earlier conclusion (Crowther et al.,
1975) that the pre-treatment TLI corre-
lated with the length of the first remission
in AML is no longer tenable. The number
of patients in this remission group has
increased from 21 to 57. There is still a
trend in favour of patients with a TLI
below 10% but this is not significant
(P=0.4) (Fig. 3). Analysis of the 46
patients with MI, M2 and M4 in this remis-
sion group shows that there was a ten-
dency for more patients with TLI over
10% to relapse in less than 8 months.
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FIG. 5. Relationship between the pre-treat-
ment TLI of marrow blasts and response to
in'itial tlherapy in ALL.
However, the TLI did not correlate with
remission length. Durie et al. (1977) noted
a negative correlation between remission
length and TLI, but the full data do not
seem to lhave been published.
It can be supposed that the patients
seen since 1974 behaved differently to
those seen in 1970-1974. Analysis of the
57 remission patients according to treat-
ment shows no correlation between TLI
and the induction therapy, maintenance
therapy or immunotherapy used. The
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length of remission in some of the latter
patients given more intensive induction
chemotherapy was greater (Lister et al.,
1980) but there was no correlation with
the TLI.
There have been several reports that a
higher TLI in patients with AML corre-
lated with the achievement of complete
remission (Burke & Owens, 1971; Cheung
et al., 1972; Hart et al., 1974; Vogler
et al., 1974; Zittoun et al., 1975). Other
reports have shown no correlation between
the TLI and attainment of complete
remission (Amadori et al., 1978; Arlin
et al., 1976; Crowther et al., 1975; Durie
et al., 1977; Vogler et al., 1976; Wantzin,
1977). It is noteworthy that these papers
deal mainlywith small numbers ofpatients
andthe correlation claimeddoesnotalways
stand furtheranalysis.
Our data reported here on 172 patients
with AML and 29 adult patients with
ALL (Fig. 1-7) are in agreement with
those of the above authors, who found no
correlation between TLI and response to
treatment, remission length or survival.
A detailed breakdown of our data on
TLI in AML is given in Table III. From
these data it is clear that the TLI is not
a useful parameter in AML. Very little
data on adult ALL have been published,
but the lack of correlation between the
TLI and the response to treatment,
remission length or survival in our 29
t 67/c
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Fio. 6. Relationship between the pre-treatment TLI of marrow blasts ancl length of first remission
in ALL ( 0, still in remission).
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cases (Fig. 5, 6, 7) contrasts with the
data on childhood AL,L (Scarife et al.,
1980).
Acute leukaemia blast cells consist of
two distinct populations, dividing and
non-dividing, t,he latter group being the
larger. The earliest cells divide, decrease
in size and eventually cease to divide.
As cells pass through- this sequence, the
GI inter-mitotic phase becomes longer.
The non-dividing cells are probably in a
(G phase so long that they die before
reaching another cell division. The earliest
cells have a TLI > 4000, whereas the later
cells have a TLI < 3 o ((G,avosto et al.,
1967; Hillen et al., 1975; Priesler et al.,
1977; Sewell, 1967). The observed TLI
falls somewhere between t,he two extremes
but is influenced by the relative proportion
ofnon-dividing cells and the rate at which
cells die. A TLI of 20% may reflect fewer
non-dividing cells rather than greater
disease activity than a TLI of 5%0. It is
initeresting to note that although the
range of the TLI in our 201 patients was
1-86%, only 23 had a TLI over 20% and
only 9 of these had a TLI over 300° (Fig.
1,5.).
Protein synthesis is another factor
which must be taken into account. In
acute leukaemia there is an accumulation
of non-dividing cells which fail to mature.
Maturation is essentially the synthesis of
enzyme systems. The failure of blast cells
to mature may be the result of failure of
protein synthesis, for which there is auto-
radiographic evidence (Gavosto et al.,
1960; Sewell, 1972). In acute leukaemia,
blast cells readily label with RNA pre-
cursors but are largely unlabelled by pro-
tein precursors. Further evidence for the
failure of these blast cells to make protein
has come from studies of ribosomal RNA
(rRNA). It has been shown that rRNA in
acute-leukaemia blast cells is poorly
methylated and largely fails to undergo
processing to form the 18S and 28S
molecules essential for protein synthesis
(Torelli et al., 1970; Seeber et al., 1974).
Similar changes in rRNA are seen in
growing cells treated with inhibitors of
protein synthesis (Craig & Perry, 1970).
The failure of protein synthesis in acute-
leukaemia blast cells is important as far
as the TEI is concerned, because inhibition
of protein synthesis has a profound effect
on DNA synthesis; entry into S phase is
blocked and cells in S cease to synthesize
DNA (Brown et al., 1970).
The progression from dividing to non-
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dividing cells, with prolongation of G1
which is seen in acute leukaemia, may thus
be secondary to a failure of protein syn-
thesis. Evidence that the failure ofprotein
synthesis may be due to altered transfer
RNA continues to accumulate (Sewell,
1967; Weinstein et al., 1971; Harrap,
1978).
Other factors which affect TLI, but
about which little is known, are variations
in TLI from site to site in the marrow,
dilution of the marrow sample with peri-
pheral blood and the ability of blast cells
to incorporate dT via thymidine kinase.
All these considerations point to a
complex situation in which many factors
affect the TLI of blast cells in acute
leukaemia, and the failure of the TLI to
correlate with clinical and haematological
parameters is thus not surprising.
Flow cytometry offers a means of
obtaining more detailed information about
cell kinetics, and there is hope that some
of these data will help to predict response
to treatment and to determine the value
of different drugs (Cullen, 1978; Fulwyler,
1980; Hillen et al., 1975).
This work was supported by the Imperial Cancer
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